Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Differential Expression and Analysis of Peripheral Plasma Exosome miRNA in Patients With Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Other: exosome
Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not yet recruiting

The Impact of Anxiety, Stress and Pain in the Early Phase of Myocardial Infarction on the Development of Anxiety Symptoms and Posttraumatic Stress Disorder in the Long Term Outcome

Condition:   Myocardial Infarction
Intervention:   Other: No intervention
Sponsor:   Medical University of Graz
Not yet recruiting

Myocardial Infarction, COmbined-device, Recovery Enhancement Study

Conditions:   Acute Myocardial Infarction;   Coronary Artery Disease;   Acute Coronary Syndrome;   Myocardial Infarction
Intervention:   Device: Corrie Digital Health platform
Sponsors:   Johns Hopkins University;   Apple Inc.;   iHealth
Active, not recruiting

Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China

Condition:   ST Elevation Myocardial Infarction
Intervention:   Behavioral: Quality improvement strategies and tools
Sponsor:   China National Center for Cardiovascular Diseases
Recruiting

TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

Condition:   Myocardial Infarction
Intervention:   Drug: Beta blocker
Sponsor:   Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Recruiting

A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

Condition:   ST Elevation Myocardial Infarction
Interventions:   Biological: MEDI6012;   Other: Placebo
Sponsors:   MedImmune LLC;   Thrombolysis in Myocardial Infarction (TIMI) Study Group
Recruiting

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Condition:   Myocardial Infarction
Intervention:  
Sponsors:   Duke University;   Chiesi Farmaceutici S.p.A.
Recruiting

High-Intensity Interval Training Early After Left Ventricular Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Other: HIIT;   Other: MICE
Sponsor:   University Hospital Inselspital, Berne
Recruiting

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

Conditions:   Myocardial Infarction;   Myocardial Infarction, Acute;   Myocardial Infarction Old
Intervention:   Device: BioMonitor
Sponsor:   Biotronik SE & Co. KG
Recruiting

The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor

Conditions:   STEMI;   STEMI - ST Elevation Myocardial Infarction
Interventions:   Drug: Paracetamol;   Drug: Fentanyl
Sponsors:   A.H. Tavenier;   Isala
Recruiting

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Active, not recruiting

Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction

Condition:   Cardiogenic Shock
Intervention:   Device: Extra-Corporal Life Support (ECLS)
Sponsor:   Klinikum der Universitaet Muenchen
Completed

Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea

Conditions:   Ischemic Heart Disease;   Acute Myocardial Infarction
Interventions:   Biological: Stage 1-Low dose VM202RY;   Biological: Stage 1-Middle dose VM202RY;   Biological: Stage 1-High dose VM202RY;   Drug: Stage 2-Placebo;   Biological: Stage 2-Low dose VM202RY;   Biological: Stage 2-High dose VM202RY;   Device: C-Cathez® Catheter
Sponsor:   Helixmith Co., Ltd.
Withdrawn

The Study Design of a Mobile Health (mHealth) Technology Associated Improvement of Drug Adherence in Patients With Acute Myocardial Infarction and Protocol for the Randomized, Controlled Trial(RESCIND-3)

Condition:   Coronary Artery Disease
Interventions:   Behavioral: Usual Text Messages;   Behavioral: Personalized reminders;   Behavioral: Internet-based counselling
Sponsors:   Guangdong General Hospital;   Maoming General Hospital;   Dongguan People's Hospital;   First People's Hospital, Shunde China;   Guangzhou Panyu Central Hospital
Recruiting

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Conditions:   Coronary Artery Disease;   STEMI - ST Elevation Myocardial Infarction
Interventions:   Drug: Cangrelor;   Drug: Tirofiban;   Drug: Prasugrel
Sponsor:   University Hospital Inselspital, Berne
Active, not recruiting

Colchicine Cardiovascular Outcomes Trial (COLCOT)

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Interventions:   Drug: colchicine;   Drug: colchicine placebo
Sponsor:   Montreal Heart Institute
Completed

Technical Development of Cardiovascular Magnetic Resonance Imaging

Conditions:   Cardiomyopathy;   Congenital Heart Disease;   Cardiovascular Disease;   Cardiac Magnetic Resonance Imaging;   Acute Myocardial Infarction
Intervention:   Device: Siemens MRI scanner
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended

Coronary Artery Healing and Bioresorbable Scaffold

Conditions:   Myocardial Infarction;   Coronary Artery Disease
Interventions:   Device: OCT guided PCI;   Device: Angiography guided PCI
Sponsor:   Odense University Hospital
Active, not recruiting

The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients

Conditions:   Myocardial Infarction;   Psychosocial Factors
Interventions:   Behavioral: Gratitude Journaling Plus SOC;   Behavioral: Memorable Events Journaling Plus SOC
Sponsors:   University of California, San Diego;   San Diego Veterans Healthcare System
Completed

Randomization of Single vs Multiple Arterial Grafts (ROMA) in Female Patients

Conditions:   Heart Diseases;   Coronary Artery Disease
Interventions:   Procedure: Procedure: Single arterial graft;   Procedure: Procedure: Multiple arterial grafting
Sponsors:   Maastricht University Medical Center;   Oxford University Hospitals NHS Trust;   University of Göttingen;   New York Presbyterian Hospital;   Sunnybrook Health Sciences Centre
Not yet recruiting

A Single Arm Study With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

Condition:   Coronary Artery Disease
Intervention:   Combination Product: Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Sponsor:   Medtronic Vascular
Active, not recruiting

A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients

Condition:   Coronary Artery Disease
Interventions:   Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System;   Device: Biosensors BioFreedom BA9 Drug Coated Coronary Stent
Sponsor:   Medtronic Vascular
Active, not recruiting

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Population Health Research Institute;   Janssen Research & Development, LLC
Active, not recruiting

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

Conditions:   Heart Failure;   Myocardial Infarction
Interventions:   Biological: High Dose Trivalent Influenza Vaccine;   Biological: Standard Dose Quadrivalent Influenza Vaccine
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   University of Wisconsin, Madison;   University of Toronto;   Boston VA Research Institute, Inc.;   Patient-Centered Outcomes Research Institute
Active, not recruiting

Brilinta Clinical Experience Investigation

Condition:   Acute Coronary Syndrome, Old Myocardial Infarction
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis

Condition:   Myocardial Infarction
Intervention:   Other: Stress Challenge
Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Condition:   Acute Myocardial Infarction
Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
Sponsor:   Novartis Pharmaceuticals
Recruiting

BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?

Conditions:   Hypertension;   Dementia
Intervention:   Other: Bedtime administration of the participant's pre-existing antihypertensive medications
Sponsors:   University of Alberta;   Alberta Innovates Health Solutions;   Canadian Institutes of Health Research (CIHR);   EnACt
Not yet recruiting

Neuropsychological Outcome After Cardiac Arrest

Conditions:   Heart Arrest, Out-Of-Hospital;   Hypoxia-Ischemia, Brain;   Cognition Disorders;   Psychological Distress;   Fatigue;   Insomnia
Intervention:   Diagnostic Test: Neuropsychological assessment
Sponsors:   Region Skane;   Lund University;   Halmstad County Hospital;   Sahlgrenska University Hospital, Sweden;   Basildon and Thurrock University Hospitals NHS Foundation Trust;   Cardiff and Vale University Health Board;   Aarhus University Hospital
Recruiting

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions:   Cardiovascular Disease;   Diabetes Mellitus, Type 2
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Completed

Disrupt CAD III With the Shockwave Coronary IVL System

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:   Device: Lithotripsy
Sponsor:   Shockwave Medical, Inc.
Recruiting

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Myocardial Infarction;   Stent Thrombosis;   Cardiovascular Diseases
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Action Research Group;   AstraZeneca
Recruiting

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
Interventions:   Device: Orbital Atherectomy;   Device: Balloon
Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
Recruiting

Physical Activity After Cardiac Arrest; a Sub-study in the Target Temperature Management Trial 2

Conditions:   Heart Arrest, Out-Of-Hospital;   Physical Activity
Intervention:   Diagnostic Test: Measures of physical activity and kinesiophobia
Sponsors:   Region Skane;   Lund University;   Halmstad County Hospital;   Sahlgrenska University Hospital, Sweden;   Stockholm South General Hospital
Enrolling by invitation

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting

e-NOBORI Observational Registry of Nobori DES

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Terumo Europe N.V.
Completed

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   NYU Langone Health;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Active, not recruiting

Prospective Multicenter Study for Early Evaluation of Acute Chest Pain

Conditions:   Chest Pain;   Acute Aortic Dissection;   Pulmonary Embolism;   Acute Myocardial Infarction Type 1;   Acute Coronary Syndrome
Interventions:   Diagnostic Test: Coronary angiography;   Diagnostic Test: CT angiography of aorta;   Diagnostic Test: CT angiography of pulmonary arteries.;   Diagnostic Test: Electrocardiogram;   Diagnostic Test: Cardiac Troponin
Sponsor:   West China Hospital
Not yet recruiting

Genetic Factors in Atherosclerosis

Condition:   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
Sponsor:   CSL Behring
Recruiting

Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   Instituto Mexicano del Seguro Social
Recruiting

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Intervention:   Drug: Evolocumab
Sponsor:   Tianjin Chest Hospital
Not yet recruiting

Colchicine in Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Intervention:   Drug: Colchicine vs Placebo
Sponsors:   VA Office of Research and Development;   NYU Langone Health
Active, not recruiting

Vitamin D and Omega-3 Trial (VITAL)

Conditions:   Cancer;   Cardiovascular Disease
Interventions:   Dietary Supplement: vitamin D3;   Drug: omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
Sponsors:   Brigham and Women's Hospital;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   Office of Dietary Supplements (ODS);   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Conditions:   Overweight;   Obesity
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Active, not recruiting

Creating an Optimized Technology-Based Weight Loss Program for Cardiac Rehabilitation Patients

Conditions:   Cardiovascular Diseases;   Obesity
Interventions:   Behavioral: Online Behavioral Weight Loss Program;   Behavioral: Physical Activity Intervention;   Behavioral: Bite Counter;   Behavioral: Virtual Reality;   Behavioral: Virtual Meetings
Sponsors:   The Miriam Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Safety and Efficacy of Delayed Continuous Use of Bivalirudin 4 Hours After ePCI (COBER Study)

Condition:   Coronary Heart Disease
Interventions:   Drug: delayed continuous use of bivalirudin;   Drug: bivalirudin use during ePCI
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting

Hepatitis C Treatment and Atherosclerosis

Conditions:   Chronic Hepatitis C;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Non-Interventional Study on Effectiveness of Elxaban Tab. in Patients With Non-valvular Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Yonsei University
Active, not recruiting

Absorb IV Randomized Controlled Trial

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: Absorb BVS;   Device: XIENCE
Sponsor:   Abbott Medical Devices
Active, not recruiting

Long-term Outcome of Deferred Lesion Based on FFR

Condition:   Myocardial Ischemia
Intervention:   Diagnostic Test: fractional flow reserve
Sponsor:   University Hospital of Ferrara
Active, not recruiting

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

Condition:   End-Stage Kidney Disease
Interventions:   Other: Default dialysate sodium concentration of 137mmol/l;   Other: Default dialysate sodium concentration of 140mmol/l
Sponsors:   The George Institute;   Australasian Kidney Trials Network
Recruiting

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Terminated

Circadian Rhythms and Cardiovascular Risk

Condition:   Obstructive Sleep Apnea
Intervention:   Behavioral: Forced Desynchrony
Sponsor:   Oregon Health and Science University
Recruiting

Effect of Weight Loss Surgery on Stem Cells.

Conditions:   Obesity, Morbid;   Stem Cells;   Cardiovascular Morbidity
Intervention:   Procedure: Bariatric (weight loss) surgery
Sponsors:   St. Michael's Hospital, Toronto;   Humber River Hospital;   University of Western Ontario, Canada
Completed

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Condition:   Childhood Malignant Neoplasm
Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting

XIENCE 28 USA Study

Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
Sponsor:   Abbott Medical Devices
Recruiting

Impacts of Omega-3-PUFA Enriched Chicken-meat and Eggs in Healthy Humans

Condition:   Healthy Diet
Interventions:   Other: Control Chicken-meat;   Other: Control Eggs;   Other: Omega-3-PUFA Enriched Chicken-meat;   Other: Omega-3PUFA Enriched Eggs
Sponsors:   Alice Stanton;   Devenish Nutrition, Belfast, United Kingdom.;   Beaumont Hospital;   University College Dublin
Active, not recruiting

Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings

Condition:   Hypertension
Intervention:   Other: Incentivized Care
Sponsor:   Virginia Commonwealth University
Recruiting

The Gore SCAFFOLD Clinical Study

Conditions:   Carotid Artery Disease;   Carotid Artery Stenosis
Intervention:   Device: Carotid Artery Stenting
Sponsor:   W.L.Gore & Associates
Active, not recruiting

Insulin Resistance and Atherosclerosis in Women With Lupus

Conditions:   Systemic Lupus Erythematosus;   Insulin Resistance;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Aspirin;   Drug: Lipitor
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

BIOSOLVE-IV Magmaris Swiss Satellite Registry

Condition:   Coronary Artery Disease
Intervention:   Device: Magmaris Resorbable Magnesium Scaffold (RMS)
Sponsor:   University Hospital, Geneva
Recruiting

Effect of Diet on Vascular Disease in Pre-Menopausal Women

Conditions:   Cardiovascular Diseases;   Vascular Disease;   Inflammation;   Insulin;   Triglycerides
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   ST-segment Elevation Myocardial Infarction (STEMI);   Non-ST-Segment Elevation Myocardial Infarction (NSTEMI);   Angina, Stable
Intervention:   Behavioral: HeartHome
Sponsors:   University of North Carolina, Chapel Hill;   Duke University
Not yet recruiting

Preventing Adverse Cardiac Events in COPD

Conditions:   Chronic Obstructive Pulmonary Disease;   Cardiovascular Diseases
Interventions:   Drug: Bisoprolol;   Drug: Placebo Oral Tablet
Sponsor:   The George Institute
Not yet recruiting

Post Market Surveillance of SeQuent Please Neo With Scoring Balloon

Condition:   Coronary Artery Disease (CAD)
Intervention:   Device: Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation
Sponsors:   B. Braun Melsungen AG;   Klinikum Ernst von Bergmann Augenklinik Laserzentrum
Active, not recruiting

Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)

Conditions:   Acute Ischemic Stroke;   Atrial Fibrillation;   Extracranial Atherosclerosis;   Intracranial Atherosclerosis;   Coronary Artery Atherosclerosis;   Peripheral Artery Stenosis;   Anticoagulant;   Antiplatelet
Intervention:   Drug: Edoxaban Monotherapy
Sponsors:   Asan Medical Center;   Samsung Medical Center;   Myongji Hospital;   Ewha Womans University;   Chonbuk National University;   Pusan National University Hospital;   Korea University;   Keimyung University Dongsan Medical Center;   Chonnam National University Hospital;   Korea University Guro Hospital;   Chungnam National University Hospital;   Chung-Ang University Hosptial, Chung-Ang University College of Medicine;   Kyungpook National University Hospital;   Dongtan Sacred Heart Hospital;   Eulji University Hospital
Recruiting

Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Terumo Europe N.V.
Active, not recruiting

Carolina Heart Alliance Networking for Greater Equity

Condition:   Cardiovascular Disease (CVD)
Intervention:   Behavioral: CHANGE Study
Sponsors:   University of North Carolina, Chapel Hill;   Centers for Disease Control and Prevention
Completed

The First-In-Man Pilot Study of Firehawk

Condition:   Coronary Heart Disease
Intervention:   Device: Rapamycin target-eluting Coronary Stent System
Sponsor:   Shanghai MicroPort Medical (Group) Co., Ltd.
Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Condition:   Anemia in Subjects With DD-CKD
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Active, not recruiting

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Conditions:   Anemia;   Dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: Darbepoetin alfa
Sponsor:   Akebia Therapeutics
Active, not recruiting

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Active, not recruiting

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Active, not recruiting

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Conditions:   Type2 Diabetes;   Dyslipidemia
Interventions:   Drug: K-877;   Drug: Placebo
Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
Recruiting

Morbidity and Mortality in Autonomous Cortisol Secretion

Conditions:   Adrenal Incidentaloma;   Cortisol Overproduction
Intervention:  
Sponsor:   Region Skane
Active, not recruiting

Effect of a Multi-component Education Program on Salt Reduction in Adults

Conditions:   Blood Pressure;   Hypertension
Interventions:   Behavioral: Salt reduction program;   Behavioral: Healthy lifestyle program
Sponsors:   Academia Cuf Descobertas;   NOVA Medical School;   Jeronimo Martins
Completed

Central Hemodynamic and Sodium Urinary

Condition:   Hypertension
Intervention:   Diagnostic Test: Evaluate if the individuals are resistant hypertensive patients
Sponsors:   Hospital de Base;   Sao Jose do Rio Preto Medical School
Active, not recruiting

Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Angioplasty, Transluminal, Percutaneous Coronary
Intervention:   Device: implantation of Kaname Cobalt-Chromium coronary stent
Sponsor:   Terumo Europe N.V.
Completed

Mindful Hearts Study: Mindfulness to Reduce Stress

Conditions:   Cardiovascular Disease;   Psychological Stress;   Stroke;   Coronary Artery Disease
Interventions:   Behavioral: Mindfulness Based Stress Reduction;   Behavioral: Health Education Program
Sponsor:   VA Office of Research and Development
Completed

Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting

The Effects of Intravenous Anesthetics and Inhaled Anesthetics on Patients' Postoperative Sleep

Condition:   Sleep Disturbance
Intervention:   Drug: Propofol ; Sevoflurane
Sponsor:   Yanchao Yang
Not yet recruiting

Coronary Steal Via Natural Internal Mammary Artery-To-Coronary Artery Bypasses

Conditions:   Coronary Artery Disease;   Ischemia
Intervention:   Other: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
Sponsor:   University Hospital Inselspital, Berne
Recruiting

Undiagnosed Sleep Apnea and Bypass OperaTion

Condition:   Sleep Apnea
Intervention:  
Sponsor:   National University, Singapore
Active, not recruiting

Safety, Efficacy, Longitudinal Costs and Patient-Centered Outcomes Using a TAAA Debranching Device

Condition:   Thoracoabdominal Aortic Aneurysm
Interventions:   Device: Visceral Manifold and Thoracic Bifurcation;   Device: Unitary Manifold;   Device: TAAA Debranching Stent Graft System
Sponsor:   Johns Hopkins University
Enrolling by invitation

Effect of Efpeglenatide on Cardiovascular Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide (SAR439977);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

Heart Failure (HF) Interatrial Shunt Study 1

Condition:   Chronic Heart Failure
Intervention:   Procedure: V-Wave
Sponsor:   V-Wave Ltd
Withdrawn

INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)

Condition:   Contraception
Intervention:  
Sponsors:   Center for Epidemiology and Health Research, Germany;   Bayer
Completed

Acute Kidney Injury Genomics and Biomarkers in TAVR Study

Conditions:   Acute Kidney Injury;   Renal Insufficiency, Chronic;   Heart Failure;   Myocardial Infarction;   Arrhythmias, Cardiac;   Stroke
Intervention:   Procedure: Transcatheter Aortic Valve Replacement
Sponsor:   University of Texas Southwestern Medical Center
Recruiting

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Condition:   Carotid Artery Stenosis
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Aspirin
Sponsor:   University Hospital, Basel, Switzerland
Recruiting

Distal Radial Artery vs. Forearm Radial Artery For Cardiac Catheterization

Conditions:   Coronary Artery Disease;   Angina, Unstable;   Angina, Stable;   Non STEMI;   Non ST Segment Elevation Myocardial Infarction;   Acute Coronary Syndrome;   Atheroscleroses, Coronary;   Atherosclerotic Heart Disease With Ischemic Chest Pain;   Chest Pain;   Myocardial Infarction;   Myocardial Ischemia;   ST-segment Elevation Myocardial Infarction (STEMI)
Interventions:   Procedure: distal radial artery access in coronary angiography and angioplasty;   Procedure: Forearm radial artery access in coronary angiography and angioplasty
Sponsor:   An-Najah National University
Recruiting

A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

Conditions:   Coronary Heart Disease;   Anemia;   Bronchial Asthma;   Stroke;   Epilepsy;   Parkinson's Disease;   Heart Rhythm Disorders;   Alzheimer's Disease;   Neuromuscular Diseases;   Diabetes;   Chronic Heart Failure;   Chronic Obstructive Pulmonary Disease;   Chronic Kidney Diseases
Intervention:  
Sponsors:   Russian Federation of Anesthesiologists and Reanimatologists;   Kuban State Medical University
Recruiting

Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )

Condition:   Coronary Heart Disease
Interventions:   Device: drug coated balloon;   Device: drug eluted stent
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Not yet recruiting

Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: SEL;   Drug: Placebo
Sponsor:   Gilead Sciences
Recruiting

Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization

Conditions:   Peripheral Arterial Disease;   Endovascular Procedures
Interventions:   Drug: Aspirin;   Drug: Clopidogrel
Sponsor:   University Hospitals Cleveland Medical Center
Withdrawn

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Empagliflozin
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention

Condition:   Coronary Disease
Interventions:   Device: OCT;   Device: Angiography
Sponsors:   Takashi Kubo, MD;   Daiichi Sankyo, Inc.
Active, not recruiting

Fastigial Nucleus Stimulation for Coronary Heart Disease

Condition:   Coronary Disease
Interventions:   Device: Fastigial Nucleus Stimulation;   Drug: Standard treatment
Sponsors:   Affiliated Hospital of North Sichuan Medical College;   the Third Hospital of Mianyang
Enrolling by invitation

Cost-effectiveness and Safety of the CADScorSystem in Patients With Symptoms Suggestive of Stable Coronary Artery Disease.

Condition:   Angina, Stable
Intervention:   Device: CAD-score
Sponsors:   Bispebjerg Hospital;   Region Hovedstaden;   Larix A/S;   Acarix;   Kai Hansens Fond;   Kai Houmann Nielsens Fond
Active, not recruiting

Safety and Efficacy of Low Temperature Rota-flush Solution in Patients With Severe Calcified Lesion (LOTA-II)

Condition:   Myocardial Injury
Intervention:   Other: low temperature rota-flush solution
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting

Improving Chronic Disease Management With Pieces

Conditions:   Chronic Kidney Disease;   Diabetes;   Hypertension;   High BP;   Type 2 Diabetes
Intervention:   Other: Collaborative Model of Primary care and Subspecialty care
Sponsors:   University of Texas Southwestern Medical Center;   Parkland Center for Clinical Innovation;   Parkland Health & Hospital System;   Texas Health Resources;   Connecticut Center for Primary Care;   Dallas VA Research Corporation;   G-Health Enterprises;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI)
Completed

The Randomized OPTIMAL-ACT Trial

Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Anticoagulant-induced Bleeding;   Coronary Syndrome
Intervention:   Drug: Unfractionated heparin
Sponsor:   Mayo Clinic
Recruiting

Switch From Ticagrelor to Clopidogrel in ACS Patients After PCI

Condition:   Acute Coronary Syndrome (ACS)
Intervention:   Drug: Switch ticagrelor to clopidogrel
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor

Conditions:   Ticagrelor;   Pharmacokinetics;   Pharmacodynamics;   Pharmacogenomics;   Accurate Medication
Intervention:   Genetic: detection of genotype
Sponsor:   Cui Yimin
Recruiting

The Cerebral-Coronary Connection (C3) Study

Conditions:   Ischemic Heart Disease;   Microvascular Coronary Artery Disease;   Depression;   Endothelial Dysfunction;   Inflammation
Intervention:   Procedure: Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)
Sponsors:   Instituto de Salud Carlos III;   Hospital San Carlos, Madrid
Recruiting

Prognostic Value of Myocardial Fibrosis in Severe Aortic Valve Stenosis

Condition:   Aortic Stenosis, Calcific
Intervention:   Diagnostic Test: Cardiac magnetic resonance imaging
Sponsors:   Vilnius University;   Research Council of Lithuania
Recruiting

STOP Persistent AF

Condition:   Atrial Fibrillation
Intervention:   Device: Arctic Front Advance Cardiac CryoAblation Catheter
Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
Completed

Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

Condition:   Acute Respiratory Distress Syndrome (ARDS)
Interventions:   Drug: Inhaled Carbon Monoxide at 100ppm (4 participants);   Drug: Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants);   Drug: Inhaled Carbon Monoxide at 200ppm (4 participants);   Drug: Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
Sponsors:   Brigham and Women's Hospital;   Weill Medical College of Cornell University;   Massachusetts General Hospital;   Duke University
Completed

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

Condition:   CAD
Interventions:   Device: MRI scan x 1 Healthy Volunteer;   Device: MRI scan x 2 Healthy Volunteer;   Device: MRI scan x 2 - CAD patients;   Device: MRI scan x 2- non CAD patients
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Device: RF Ablation with QDOT Micro
Sponsor:   Biosense Webster, Inc.
Active, not recruiting

Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Device: Catheter ablation with EPU
Sponsor:   Biosense Webster, Inc.
Recruiting

Early Detection of Myocardial Ischaemia in Suspected Acute Coronary Syndromes by Apo J-Glyc

Condition:   Myocardial Ischemia
Intervention:   Diagnostic Test: Blood collection
Sponsor:   Glycardial Diagnostics S.L.
Recruiting

Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure

Condition:   Heart Failure
Intervention:   Biological: intracoronary infusion of autologous bone marrow-derived cells
Sponsor:   Johann Wolfgang Goethe University Hospital
Active, not recruiting

Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)

Condition:   Coronary Artery Disease (CAD)
Intervention:   Device: stenting with the Coroflex ISAR sirolimus-eluting stent
Sponsors:   B. Braun Melsungen AG;   Charite University, Berlin, Germany
Active, not recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Conditions:   Acute Coronary Syndrome;   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting

Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome

Conditions:   Obstructive Sleep Apnea;   Acute Coronary Syndrome
Interventions:   Device: Continuous Positive Airway Therapy;   Behavioral: Sleep-Study Guided Multidisciplinary Therapy
Sponsor:   National University, Singapore
Active, not recruiting

Lipid Profile and Diabetes Mellitus in People With HIV

Conditions:   HIV Infections;   Dyslipidemias;   Diabetes Mellitus;   Cardiovascular Risk Factor
Intervention:  
Sponsors:   Igor Grabovac;   Merck Gesellschaft mbH, Austria
Not yet recruiting

No-Touch Versus Conventional Saphenous Vein Harvesting Technique

Condition:   Coronary Artery Disease
Interventions:   Procedure: No-Touch vein harvesting technique;   Procedure: Conventional vein harvesting
Sponsor:   China National Center for Cardiovascular Diseases
Active, not recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Active, not recruiting

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

Condition:   Bicuspid Aortic Valve
Intervention:   Device: Medtronic TAVR Systems
Sponsor:   Medtronic Cardiovascular
Recruiting

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

Condition:   Atherosclerosis
Interventions:   Drug: Rivaroxaban (BAY59-7939, Xarelto);   Drug: Acetylsalicylic acid
Sponsors:   Bayer;   Janssen, LP
Recruiting

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor;   Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

Condition:   C.Surgical Procedure; Cardiac
Interventions:   Procedure: Acute normovolemic hemodilution;   Procedure: Standard care
Sponsor:   Università Vita-Salute San Raffaele
Recruiting

Registration of Idarucizumab for Patients With IntraCranial Hemorrhage

Condition:   Intracranial Hemorrhage
Interventions:   Drug: Dabigatran Etexilate Oral Capsule [Pradaxa];   Drug: Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND];   Drug: Vitamin K antagonist
Sponsor:   University Hospital, Essen
Recruiting

Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy

Condition:   Kidney Cancer
Interventions:   Device: Hemostatic Agent;   Other: No Hemostatic Agent
Sponsor:   University of Chicago
Recruiting

Observational Study of Cardiovascular Disease.

Conditions:   Cardiovascular Diseases;   Cardiovascular Morbidity;   Coronary Heart Disease;   Low-density-lipoprotein-type
Intervention:   Other: N/A - observational study.
Sponsors:   University of Sydney;   The Thrombolysis in Myocardial Infarction Study Group, Harvard University;   Imperial College London;   University of Oslo;   Amgen
Not yet recruiting

Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES

Condition:   Coronary Artery Disease
Intervention:   Device: TCD-10023 drug eluting stent
Sponsor:   Terumo Europe N.V.
Completed

Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing

Conditions:   Dyspnea;   Heart Failure With Preserved Ejection Fraction
Intervention:   Diagnostic Test: Lung ultrasound
Sponsor:   Mayo Clinic
Not yet recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin;   Drug: Antiplatelet drugs
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting

Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients

Condition:   Endstage Renal Disease
Intervention:  
Sponsor:   University Hospital, Basel, Switzerland
Active, not recruiting

SPYRAL HTN-ON MED Study

Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
Sponsor:   Medtronic Vascular
Recruiting

Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis

Condition:   Aortic Valve Stenosis
Intervention:   Device: MDT-2111 TAVI 23 mm
Sponsor:   Medtronic Cardiovascular
Completed

Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial

Conditions:   Stroke Hemorrhagic;   Intracerebral Haemorrhage
Intervention:   Drug: Tranexamic Acid
Sponsor:   Kwong Wah Hospital
Recruiting

[Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients]

Conditions:   Vasoplegic Syndrome;   Liver Transplant; Complications
Interventions:   Drug: Hydroxocobalamin;   Drug: Methylene Blue
Sponsor:   Mayo Clinic
Not yet recruiting

A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

Condition:   Sphingomyelin Lipidosis
Intervention:   Procedure: Investigational Procedures
Sponsor:   Sanofi
Recruiting

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

The Combined Portfolio Diet and Exercise Study

Conditions:   Cardiovascular Diseases;   Hypercholesterolemia;   Type 2 Diabetes;   Metabolic Syndrome
Interventions:   Behavioral: Portfolio diet and structured exercise;   Behavioral: DASH-like diet and structured exercise;   Behavioral: Portfolio diet and routine exercise;   Behavioral: DASH-like diet and routine exercise
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Institutes of Health Research (CIHR);   University of Toronto;   Laval University;   University of Manitoba;   University of British Columbia
Recruiting

GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy

Conditions:   Coronary Artery Disease;   Gastroesophageal Reflux Disease
Interventions:   Drug: Indobufen and aspirin mimetic;   Drug: Aspirin and indobufen mimetic
Sponsor:   Beijing Anzhen Hospital
Not yet recruiting

Comparative Analysis of APACHE II and P-POSSUM

Condition:   External Causes of Morbidity and Mortality
Intervention:  
Sponsor:   Tata Main Hospital
Completed

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

Condition:   Atrial Fibrillation
Intervention:   Drug: Idarucizumab
Sponsor:   Boehringer Ingelheim
Recruiting

Carotid Artery Stenting With Cilostazol Addition for Restenosis

Condition:   In-stent Restenosis After Carotid Artery Stenting
Intervention:   Drug: Cilostazol or Non-Cilostazol
Sponsors:   Kobe City General Hospital;   Chiba University;   Nagoya University;   Mie University;   Wakayama Medical University;   Kyoto University;   Osaka University;   Kobe University;   Foundation for Biomedical Research and Innovation;   Okayama University;   Yamaguchi University Hospital;   Fukuoka University;   Nagasaki University
Completed

Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.

Condition:   Cardiogenic Shock
Interventions:   Combination Product: Hydrocortisone + Flucortac;   Other: Placebo
Sponsor:   CMC Ambroise Paré
Recruiting

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Conditions:   Hyperlipoproteinemia Type II;   Hypercholesterolemia, Familial
Interventions:   Drug: Anacetrapib;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed

The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

Conditions:   Atrial Fibrillation and Flutter;   Stroke;   Major Bleed;   End-stage Renal Disease
Intervention:   Drug: Warfarin
Sponsors:   Nicholas Carlson;   Danish Heart Foundation
Recruiting

CARDSUP - SWISS Circulatory Support Registry

Condition:   Cardiogenic Shock
Intervention:  
Sponsor:   University Hospital Inselspital, Berne
Recruiting

Statins And Cirrhosis: Reducing Events of Decompensation

Condition:   Cirrhosis
Interventions:   Drug: Placebo Oral Tablet;   Drug: Simvastatin 40mg
Sponsor:   Tamar Taddei
Not yet recruiting

Hips Screws or (Total) Hip Replacement for Undisplaced Femoral Neck Fractures in Elderly Patients (HipSTHeR)

Conditions:   Femoral Neck Fractures;   Undisplaced Fracture
Interventions:   Device: Arthroplasty;   Device: Internal Fixation
Sponsors:   Uppsala University;   The Swedish Research Council
Recruiting

Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa

Condition:   Arterial Hypertension
Interventions:   Other: dual combination;   Other: triple combination;   Other: Standard of care
Sponsors:   University Hospital, Basel, Switzerland;   Swiss National Fund for Scientific Research
Not yet recruiting

Early Versus Late Upper Extremity Mobilization After Autograft

Condition:   Burns
Interventions:   Other: Early Mobilization;   Other: Late Mobilization
Sponsor:   Sunnybrook Health Sciences Centre
Recruiting

Complex Large-bore Radial Percutaneous Coronary Intervention (PCI) Trial

Condition:   Complex Coronary Lesions
Interventions:   Procedure: radial artery access for complex PCI;   Procedure: femoral artery access for complex PCI
Sponsors:   Maatschap Cardiologie Zwolle;   Terumo Europe N.V.
Recruiting

Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)

Condition:   Renal Transplant Rejection
Intervention:   Drug: Antithymocyte Immunoglobulin (Rabbit)
Sponsors:   Prof. Dr. Petra Reinke;   Institut Klinické a Experimentální Medicíny
Recruiting

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

Condition:   Renal Transplant
Intervention:   Drug: Arm 1 Everolimus/Reduced dose tacrolimus
Sponsors:   University of Toledo Health Science Campus;   Novartis Pharmaceuticals
Active, not recruiting

The CARILLON Trial - Assessment of the Carillon® Mitral Contour System® in Treating Functional Mitral Regurgitation Associated With Heart Failure

Conditions:   Functional Mitral Regurgitation;   Heart Failure;   Mitral Valve Insufficiency;   Heart Diseases;   Cardiovascular Diseases;   Heart Valve Diseases
Interventions:   Device: Carillon Mitral Contour System;   Other: Guideline Directed Heart Failure Medication
Sponsor:   Cardiac Dimensions, Inc.
Recruiting

CHANGE Neo™ TA Registry With ACURATE Neo™ Aortic Bioprosthesis and ACURATE Neo™ TA Transapical Delivery System

Condition:   Aortic Stenosis
Intervention:   Device: ACURATE neo™ Aortic Bioprosthesis
Sponsor:   Symetis SA
Recruiting

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

Conditions:   Osteomyelitis;   Diabetes;   Amputation
Interventions:   Drug: Rifampin;   Drug: Riboflavin Placebo
Sponsor:   VA Office of Research and Development
Recruiting

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Condition:   Early Breast Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Pertuzumab IV;   Drug: FDC of Pertuzumab and Trastuzumab SC;   Drug: Trastuzumab IV;   Drug: Trastuzumab SC;   Procedure: Surgery;   Radiation: Post-operative Radiotherapy;   Drug: Hormone Therapy
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

Conditions:   Diabetic Retinopathy;   Diabetic Macular Edema
Interventions:   Drug: Triamcinolone Acetonide + laser;   Drug: Ranibizumab + laser;   Drug: Sham injection + laser;   Drug: Ranibizumab + deferred laser
Sponsors:   Jaeb Center for Health Research;   National Eye Institute (NEI);   Allergan;   Genentech, Inc.
Completed

OCT vs IVUS vs QCA to Guide Moderate-to-severe Calcified Lesion Stent Implantation

Conditions:   Optical Coherence Tomography;   Intravascular Ultrasound;   Angiography
Interventions:   Device: OCT guidance;   Device: IVUS guidance;   Device: QCA
Sponsor:   Shanghai MicroPort Medical (Group) Co., Ltd.
Not yet recruiting

Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice

Conditions:   Arterial Hypertension;   CHD - Coronary Heart Disease
Intervention:   Drug: bisoprolol/perindopril FDC
Sponsor:   Servier Russia
Recruiting

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed